NEW DELHI: In what could be good news for patients, Indian Patent Office (IPO) has rejected MNC AbbVie’s patent application for its blockbuster cancer drug Venetoclax citing lack of inventive step.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...

Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

As lawmakers eye tougher oversight of pharmacy benefit managers, PBMs seem to be taking their own steps to rein in practices that have invited scrutiny. However, experts remain skeptical and say it ...

Cigna's health services division Evernorth is ending drug rebates for all of its fully insured plan customers beginning in 2027. Instead, the discounted price negotiated between Evernorth's pharmacy ...

FRANKFURT (Reuters) -Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss company's shares lower, as its top-selling drug comes ...

Aldeyra Therapeutics has shaken up its drug development pipeline, stopping work on one asset in the wake of phase 2 data and swapping out two other molecules in response to recent results. The biotech ...